Bacterial Resistance and Novel Therapeutic Approaches

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Bacterial Pathogens".

Deadline for manuscript submissions: 15 February 2026 | Viewed by 527

Special Issue Editors


E-Mail Website
Guest Editor
Division of Bacteriology, Department of Infection and Immunity, School of Medicine, Jichi Medical University, Shimotsuke-shi 3290498, Japan
Interests: infectious diseases; bacterial drug resistance; Staphylococcus aureus; bacteriophage

E-Mail Website
Guest Editor
Division of Bacteriology, Department of Infection and Immunity, School of Medicine, Jichi Medical University, Shimotsuke-shi 3290498, Japan
Interests: antimicrobial resistance; staphylococcal infection; phage therapy

E-Mail Website
Guest Editor
UKM Medical Molecular Biology Institute (UMBI), Universiti Kebangsaaan Malaysia, Kuala Lumpur, Malaysia
Interests: antimicrobial resistance; Staphylococcus aureus; pathogen surveillance; infectious diseases

Special Issue Information

Dear Colleagues,

Bacterial resistance is a growing global health threat, making many antibiotics ineffective and leading to prolonged illnesses, higher mortality rates, and increased healthcare costs. Multidrug-resistant pathogens like Staphylococcus aureus and Klebsiella pneumoniae challenge healthcare systems. This Special Issue, “Bacterial Resistance and Novel Therapeutic Approaches,” aims at exploring groundbreaking research in bacterial pathogenesis, resistance mechanisms, and innovative solutions. Topics include, but are not limited to, bacteriophage therapy, antimicrobial peptides, advanced drug delivery systems, and next-generation antibiotics. Furthermore, advancements in diagnostics, biofilm eradication strategies, and immunotherapeutics offer promising avenues to counter resistant infections.

We invite original research articles, reviews, and short communications that contribute to understanding and overcoming bacterial resistance.

Topics of interest include, but are not limited to, the following:

  • Mechanisms of bacterial resistance to existing antimicrobials;
  • Innovations in phage-based therapies and bacteriophage engineering;
  • Development of novel antimicrobial agents and drug repurposing strategies;
  • Advances in diagnostic tools for resistant bacterial infections;
  • Biofilm-related infections and methods for biofilm disruption;
  • Host–pathogen interactions and immunomodulatory therapies;
  • Strategies to prevent the spread of resistant pathogens in healthcare settings;
  • Applications of artificial intelligence and omics technologies in combating bacterial resistance.

Prof. Dr. Longzhu Cui
Dr. Shinya Watanabe
Dr. Hui-min Neoh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antimicrobial resistance
  • bacteriophage therapy
  • novel antimicrobials
  • drug-resistant bacteria
  • biofilm disruption
  • innovative therapeutics
  • host–pathogen interaction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 1368 KiB  
Article
Mutational Analysis of Colistin-Resistant Pseudomonas aeruginosa Isolates: From Genomic Background to Antibiotic Resistance
by Telma De Sousa, Hsin-Yao Wang, Ting-Wei Lin, Manuela Caniça, Miguel J. N. Ramos, Daniela Santos, Catarina Silva, Sónia Saraiva, Racha Beyrouthy, Richard Bonnet, Michel Hébraud, Gilberto Igrejas and Patrícia Poeta
Pathogens 2025, 14(4), 387; https://doi.org/10.3390/pathogens14040387 - 15 Apr 2025
Viewed by 251
Abstract
This study analyzed eleven isolates of colistin-resistant Pseudomonas aeruginosa, originating from Portugal and Taiwan, which are associated with various pathologies. The results revealed significant genetic diversity among the isolates, with each exhibiting a distinct genetic profile. A prevalence of sequence type ST235 [...] Read more.
This study analyzed eleven isolates of colistin-resistant Pseudomonas aeruginosa, originating from Portugal and Taiwan, which are associated with various pathologies. The results revealed significant genetic diversity among the isolates, with each exhibiting a distinct genetic profile. A prevalence of sequence type ST235 was observed, characterizing it as a high-risk clone, and serotyping indicated a predominance of type O11, associated with chronic respiratory infections in cystic fibrosis (CF) patients. The phylogenetic analysis demonstrated genetic diversity among the isolates, with distinct clades and complex evolutionary relationships. Additionally, transposable elements such as Tn3 and IS6 were identified in all isolates, highlighting their importance in the mobility of antibiotic resistance genes. An analysis of antimicrobial resistance profiles revealed pan-drug resistance in all isolates, with a high prevalence of genes conferring resistance to β-lactams and aminoglycosides. Furthermore, additional analyses revealed mutations in regulatory networks and specific loci previously implicated in colistin resistance, such as pmrA, cprS, phoO, and others, suggesting a possible contribution to the observed resistant phenotype. This study has a strong impact because it not only reveals the genetic diversity and resistance mechanisms in P. aeruginosa but also identifies mutations in regulatory genes associated with colistin resistance. Full article
(This article belongs to the Special Issue Bacterial Resistance and Novel Therapeutic Approaches)
Show Figures

Figure 1

Back to TopTop